



RECEIVED

DEC 11 2002

TECH CENTER 1600/2900

AMENDMENT TRANSMITTAL LETTER		DOCKET NUMBER: P-UW 3570	
SERIAL NO: 09/323,738 Conf. No.: 9582	FILING DATE: June 1, 1999	EXAMINER: G. Ewoldt	GROUP ART UNIT: 1644
INVENTION: COMPOSITIONS AND METHODS FOR TREATING DIABETES			

TO COMMISSIONER FOR PATENTS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box AF, Washington, D.C., 20231 on December 3, 2002.

By: John T. Murphy Reg. No. 50,583  
December 3, 2002  
Date of Signature

Transmitted herewith is Response to Office Action mailed June 3, 2002, with Appendix A and Exhibits A, B, C and D, in the above-identified application.

- ☒ Small Entity status of this application has been established under 37 CFR 1.27 August 24, 1999.
- ☒ Petition for Extension of Time is enclosed (in duplicate).
- ☐ Terminal Disclaimer with fee under 37 C.F.R. 1.20(d) is enclosed.
- ☒ Notice of Appeal (in duplicate).
- ☒ No additional claims fee is required.
- ☐ An additional claims fee is required and has been calculated as shown below:

## CLAIMS AS AMENDED

	NUMBER AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE			FEE	
							SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	40	-	40	-	0	x	\$9	\$18	=	\$0.00	\$
INDEPENDENT CLAIMS	4	-	4	-	0	x	\$42	\$84	=	\$0.00	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			YES		X NO		\$140	\$280	=	\$0.00	\$
							TOTAL ADDITIONAL FEE			\$0.00	\$

\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.


\*\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

\*\*\* If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

Inventors: Osborne and Ramesh  
Serial No.: 09/323,738  
Filed: June 1, 1999  
Page 2

- ☐ Please charge my Deposit Account No. 03-0370 the amount of \$\_\_\_\_\_. A duplicate copy of this sheet is enclosed.
- ☒ A check in the amount of \$620.00 is enclosed, \$160.00 of which covers the appeal fee and \$460.00 of which covers the fee for a three-month extension of time.
- ☒ The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

  
\_\_\_\_\_  
John T. Murphy  
Registration No. 50,583  
CAMPBELL & FLORES LLP  
4370 La Jolla Village Drive  
7<sup>th</sup> Floor  
San Diego, California 92122  
858-535-9001  
USPTO CUSTOMER NO. 23601



RECEIVED

DEC 11 2002

TECH CENTER 1600/2900

PATENT

Our Docket: P-UW 3570

RESPONSE UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of )  
Osborne and Ramesh )  
Serial No: 09/323,738 )  
Filed: June 1, 1999 )  
For: COMPOSITIONS AND METHODS )  
FOR TREATING DIABETES )  
Box AF  
Commissioner for Patents  
Washington, D.C. 20231

Group Art Unit: 1644  
Examiner: G. Ewoldt  
Conf. No.: 9582

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box AF, Commissioner for Patents, Washington, D.C., 20231 on December 3, 2002.

By: John T. Murphy  
John T. Murphy, Reg. No. 50,583  
December 3, 2002  
Date of Signature

RESPONSE TO OFFICE ACTION

Responsive to the Office Action mailed June 3, 2002, entry of the following amendments and remarks is respectfully requested.

AMENDMENTS

In the claims

Please amend the claims as follows:

17. (Amended) A method of treating diabetes or  
forestalling a clinical symptom indicative of diabetes comprising  
implanting into an individual cells coexpressing an insulin  
precursor containing a proinsulin cleavage site and a glucose-